The invention discloses an anti-tumor CTL (cytotoxic lymphocyte) epitope peptide. The anti-tumor CTL epitope peptide comes from EphA2 (erythropoietin producing human hepatocellularcarcinoma A2) and is a nonapeptide. Amino acid sequences of the anti-tumor CTL epitope peptide are Gln-Asn-Ile-Met-Asn-Asp-Met-Pro-Ile. The invention further discloses application of the anti-tumor CTL epitope peptide to preparing tumor therapeutic DC-CIK (dendritic cells-cytokine induced killers). The anti-tumor CTL epitope peptide and the application have the advantages that prepared specific DC-CIK cells have certain hepatoma cell HepG2 (hepatocellular carcinoma) kill rate, and accordingly the anti-tumor CTL epitope peptide can be used for preparing hepatoma specific autoimmunity cells.